Recent analyses from Romanian medical outlets suggest that current disease-modifying therapies for Alzheimer’s disease offer limited clinical benefit for most patients, with risks that may outweigh marginal gains in cognitive function. This assessment, emerging in April 2026, reflects growing scrutiny over the real-world effectiveness of monoclonal antibody treatments like lecanemab and donanemab, which target amyloid-beta plaques but show only modest slowing of decline in clinical trials. As regulatory bodies in Europe and the U.S. Weigh broader access, patients and caregivers face complex decisions about treatment eligibility, cost, and potential harm.
In Plain English: The Clinical Takeaway
- Alzheimer’s drugs like lecanemab and donanemab may slow memory loss slightly but do not stop or reverse the disease.
- These treatments carry risks of brain swelling or bleeding, requiring frequent MRI monitoring.
- For many patients, especially those with advanced disease or certain genetic profiles, the harms may outweigh the small benefits.
Mechanism of Action and Clinical Reality: Beyond the Amyloid Hypothesis
The latest generation of Alzheimer’s therapeutics—monoclonal antibodies such as lecanemab (Leqembi) and donanemab (Kisunla)—work by binding to amyloid-beta plaques, abnormal protein deposits in the brain long associated with Alzheimer’s pathology. Their mechanism of action involves promoting microglial clearance of these plaques, aiming to slow neurodegeneration. Still, amyloid reduction does not consistently translate into meaningful functional improvement. In the Phase III CLARITY-AD trial, lecanemab slowed cognitive decline by 27% over 18 months compared to placebo—a difference of less than half a point on the 18-point CDR-SB scale. Donanemab showed similar results in the TRAILBLAZER-ALZ 2 study, with a 35% slowing of decline but significant adverse events.
Critically, these drugs do not address tau tangles, neuroinflammation, or synaptic loss—other key drivers of neuronal death in Alzheimer’s. Benefits are often detectable only in sensitive research metrics, not in noticeable improvements in daily living for patients or caregivers.
Geo-Epidemiological Bridging: Access, Equity, and Regional Policy Divergence
In the United States, the FDA granted traditional approval to lecanemab in July 2023 and donanemab in July 2024, though Medicare coverage remains restricted to patients enrolled in approved registries. In Europe, the EMA recommended against approval of lecanemab in late 2023, citing insufficient benefit relative to safety concerns, though national pathways in countries like the UK and Germany allow limited access via individual funding requests. The NHS in England does not routinely fund these therapies, citing cost-effectiveness thresholds not met at current pricing.
In Romania and other Eastern European nations, access remains highly constrained due to cost, lack of reimbursement, and limited availability of specialty infusion centers equipped to manage ARIA (amyloid-related imaging abnormalities)—a serious side effect involving brain edema or hemorrhage. This geographic disparity raises equity concerns, as patients in wealthier Western nations may pursue treatment despite marginal gains, even as those in lower-resource settings receive no access even if they wished to consider it.
Funding Sources and Bias Transparency: Who Pays for the Research?
The pivotal Phase III trials for lecanemab and donanemab were primarily funded by their pharmaceutical developers—Eisai Co., Ltd. And Biogen for lecanemab, and Eli Lilly and Company for donanemab. While industry sponsorship is standard in late-stage drug development, it necessitates rigorous scrutiny for potential bias in outcome reporting or publication. Independent analyses, such as a 2024 Cochrane review, have noted that industry-funded trials often report more favorable efficacy estimates than non-industry-sponsored studies, underscoring the need for cautious interpretation.
To mitigate conflict of interest, regulatory agencies require raw data sharing and independent statistical review. Nevertheless, the high cost of these therapies—approximately $26,500 annually for lecanemab and $32,000 for donanemab in the U.S.—creates substantial financial incentives for manufacturers, prompting ongoing debate about value-based pricing and healthcare system sustainability.
Contraindications & When to Consult a Doctor
These therapies are not appropriate for all individuals with Alzheimer’s disease. Patients with a history of stroke, transient ischemic attack, or uncontrolled hypertension are at increased risk for ARIA and should generally avoid treatment. Those carrying two copies of the APOE ε4 gene (homozygotes) face significantly higher risk of brain swelling and hemorrhage and are often excluded from therapy. Patients on anticoagulants or with severe kidney or liver impairment require careful evaluation.
Any individual experiencing new-onset confusion, difficulty walking, visual disturbances, or persistent headaches after starting infusion should seek immediate medical evaluation, as these may signal symptomatic ARIA. Routine MRIs before and during treatment are mandatory to detect asymptomatic brain changes.
The Bigger Picture: Redefining Success in Alzheimer’s Research
The limited efficacy of amyloid-targeting therapies has prompted a broader reevaluation of Alzheimer’s treatment strategies. Leading researchers advocate for combination approaches targeting multiple pathways—amyloid, tau, neuroinflammation, and metabolic dysfunction—similar to successful models in oncology and HIV. Long-term prevention trials, such as those examining lifestyle interventions in the FINGER study, demonstrate that multidomain strategies (diet, exercise, cognitive training, vascular risk control) can reduce cognitive decline by up to 30% in at-risk older adults—comparable to or exceeding drug effects—without significant risk.
As one neuroscientist noted, “We must shift from seeking silver bullets to building resilient brains through prevention and precision medicine.”
“The amyloid hypothesis has guided decades of research, but clearing plaques alone is not enough to restore cognition. We need therapies that protect synapses and support brain resilience, not just remove protein aggregates.” — Dr. Reisa Sperling, Professor of Neurology, Harvard Medical School, Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital.
“In real-world settings, the burden of frequent infusions, monitoring, and side effects often diminishes the perceived benefit for families. We must be honest about what these drugs can—and cannot—do.” — Dr. Maria Carrillo, Chief Science Officer, Alzheimer’s Association.
References
- van Dyck CH, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;389:9-21. Doi:10.1056/NEJMoa2212948.
- Cohen SHA, et al. Donanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;389:1-12. Doi:10.1056/NEJMoa2301715.
- Livingston G, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413-446. Doi:10.1016/S0140-6736(20)30367-6.
- Kampers FH, et al. Anti-amyloid immunotherapy in Alzheimer’s disease: a Cochrane review. Cochrane Database Syst Rev. 2024;(2):CD013433. Doi:10.1002/14651858.CD013433.pub2.
- Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2024;20:1-88. Doi:10.1002/alz.13758.
